EXAGEN INC. (XGN) Form 10-Q — Aug 4, 2026
Exagen reported revenue of $37.2 million for the six months ended June 30, 2026, representing a 13.9% increase compared to the prior year period. This growth was driven by an 11% increase in AVISE CTD test volume and a 4% rise in average selling price. Despite the revenue growth, the company recorded a net loss of $7.2 million, an improvement from the $8.2 million loss in the same period last year. Cash and cash equivalents decreased to $24.6 million, with net cash used in operating activities totaling $6.4 million for the six-month period.
Key figures
- Revenue
- 37247000
- Cash Position
- 24588000
- Revenue Growth
- 13.9%
- Shares Outstanding
- 24225339
Price after filing
Close on the filing date to close N calendar days later (from $4.67). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.